B. Riley Issues Positive Forecast for Vaxart Earnings

Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Investment analysts at B. Riley upped their Q1 2025 earnings estimates for Vaxart in a research note issued to investors on Wednesday, March 26th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn ($0.07) per share for the quarter, up from their previous forecast of ($0.09). B. Riley has a "Buy" rating and a $2.00 price objective on the stock. The consensus estimate for Vaxart's current full-year earnings is ($0.39) per share. B. Riley also issued estimates for Vaxart's Q2 2025 earnings at ($0.08) EPS and Q3 2025 earnings at ($0.07) EPS.

Vaxart Trading Down 1.9 %

Shares of Vaxart stock traded down $0.01 during trading on Monday, reaching $0.37. The company's stock had a trading volume of 2,495,969 shares, compared to its average volume of 2,383,322. Vaxart has a fifty-two week low of $0.34 and a fifty-two week high of $1.30. The company has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $0.68. The firm has a market cap of $83.32 million, a PE ratio of -0.89 and a beta of 1.69.

Vaxart (NASDAQ:VXRT - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.05. The firm had revenue of $15.19 million for the quarter, compared to the consensus estimate of $15.68 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%.

Remove Ads

Institutional Investors Weigh In On Vaxart

Several hedge funds have recently modified their holdings of the stock. XTX Topco Ltd boosted its holdings in shares of Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock valued at $116,000 after acquiring an additional 122,387 shares in the last quarter. Geode Capital Management LLC lifted its position in Vaxart by 15.8% in the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company's stock valued at $2,160,000 after purchasing an additional 346,725 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in Vaxart by 140.9% in the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 35,213 shares in the last quarter. Bank of America Corp DE increased its position in Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 17,942 shares during the period. Finally, Squarepoint Ops LLC raised its stake in shares of Vaxart by 95.0% during the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock worth $342,000 after buying an additional 251,789 shares in the last quarter. 18.05% of the stock is owned by institutional investors and hedge funds.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.